Yantai, China

Yuelei Shen

This inventor holds 1 USPTO granted patent. Top assignee: Remegen, Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yuelei Shen. Retrieved from https://idiyas.com/inventor/yuelei-shen-96jk2eqk

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Yuelei Shen

Introduction

Yuelei Shen is a prominent inventor based in Yantai, China. He has made significant contributions to the field of biotechnology, particularly in the development of innovative therapeutic solutions. His work has garnered attention for its potential impact on medical treatments.

Latest Patents

Yuelei Shen holds a patent for an "ANTI-CLAUDIN 18.2 ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOF." This patent represents a significant advancement in targeted therapies, showcasing his expertise in antibody development.

Career Highlights

Shen is currently employed at Remegen Ltd., a company known for its focus on innovative biopharmaceuticals. His role at Remegen has allowed him to further his research and development efforts in the field of antibody-drug conjugates.

Collaborations

Yuelei Shen has collaborated with notable colleagues, including Jianmin Fang and Yuanhao Li. These partnerships have contributed to the advancement of his research and the successful development of new therapeutic approaches.

Conclusion

Yuelei Shen's contributions to biotechnology and his innovative patent highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in medical treatments and therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…